A randomized controlled trial comparing perioperative vs. postoperative mFOLFOX6 for lower rectal cancer with suspected lateral pelvic lymph node metastasis (JCOG1310): a phase II/III randomized controlled trial
Authors:
- Masayuki OhueMOMasayuki Ohue
- Satoru IwasaSatoru Iwasa
- Yukihide KanemitsuYKYukihide Kanemitsu
- Manabu ShiozawaMSManabu Shiozawa
- Yusuke NishizawaYNYusuke Nishizawa
- Hideki UenoHUHideki Ueno
- Kenji KatsumataKKKenji Katsumata
- Masayoshi YasuiMYMasayoshi Yasui
- Hiroshi KatayamaHKHiroshi Katayama
- Haruhiko FukudaHFHaruhiko Fukuda
Open Access
- 30 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (8) , 850-858
Abstract
The optimal perioperative chemotherapy for lower rectal cancer with lateral pelvic lymph node metastasis remains unclear. We evaluated the efficacy and safety of perioperative mFOLFOX6 in comparison with postoperative mFOLFOX6 for rectal cancer patients undergoing total mesorectal excision with lateral lymph node dissection. We conducted an open label randomized phase II/III trial in 18 Japanese institutions. We enrolled patients with histologically proven lower rectal adenocarcinoma with clinical pelvic lateral lymph node metastasis who were randomly assigned (1:1) to receive postoperative mFOLFOX6 (12 courses of intravenous oxaliplatin [85 mg/m2] with L-leucovorin [200 mg/m2] followed by 5-fluorouracil [400 mg/m2, bolus and 2400 mg/m2, continuous infusion, repeated every 2 weeks]) or perioperative mFOLFOX6 (six courses each preoperatively and postoperatively). The primary endpoint was overall survival (OS). The trial is registered with Japan Registry of Clinical Trials, number jRCTs031180230. Between May 2015, and May 2019, 48 patients were randomized to the postoperative arm (n = 26) and the perioperative arm (n = 22). The trial was terminated prematurely due to poor accrual. The 3-year OS in the postoperative and perioperative groups were 66.1 and 84.4%, respectively (HR 0.58, 95% CI [0.14–2.45], one-sided P = 0.23). The pathological complete response rate in the perioperative group was 9.1%. Grade 3 postoperative surgical complications were more frequently observed in the perioperative arm (50.0 vs. 12.0%). One treatment-related death due to sepsis from pelvic infection occurred in the postoperative group. Perioperative mFOLFOX6 may be an insufficient treatment to improve survival of lower rectal cancer with lateral pelvic lymph node metastasis.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP22ck0106615, JP17ck0106156)
- Ministry of Health and Welfare
- National Cancer Center (2020-J-3, 29-A-3, 26-A-4, 23-A-19)
This publication has 23 references indexed in Scilit:
- Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot TrialJournal of Clinical Oncology, 2014
- Results of a Japanese Nationwide Multi-Institutional Study on Lateral Pelvic Lymph Node Metastasis in Low Rectal CancerAnnals of Surgery, 2012
- Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trialThe Lancet Oncology, 2012
- Postoperative adjuvant chemotherapy in rectal cancer operated for cure.Cochrane Database of Systematic Reviews, 2012
- Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trialThe Lancet Oncology, 2011
- Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)Cancer Chemotherapy and Pharmacology, 2010
- Lateral Lymph Node Metastasis Is a Major Cause of Locoregional Recurrence in Rectal Cancer Treated with Preoperative Chemoradiotherapy and Curative ResectionAnnals of Surgical Oncology, 2007
- Indication and Benefit of Pelvic Sidewall Dissection for Rectal CancerDiseases of the Colon & Rectum, 2006
- Late Side Effects of Short-Course Preoperative Radiotherapy Combined With Total Mesorectal Excision for Rectal Cancer: Increased Bowel Dysfunction in Irradiated Patients—A Dutch Colorectal Cancer Group StudyJournal of Clinical Oncology, 2005
- RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCERThe Lancet, 1986